圓祥生技logo
Contact LinkedIn
English
01.jpg 01-1.jpg
circle01.png circle02.png circle03.png
有效性
c01-1.svg c01-2.svg
可靠
c02-1.svg c02-1-1.svg c02-2.png
創新
c03-1.svg c03-1-1.svg c03-2.svg
bg01.svg bg02.svg
通過以機制為基礎的藥物設計<br>專注於疾病特異性靶點
通過以機制為基礎的藥物設計<br>專注於疾病特異性靶點

通過以機制為基礎的藥物設計
專注於疾病特異性靶點

Mechanism-based drug design targeting tumor-associated antigens
提供安全、有效<br>和具有成本效益的藥物
提供安全、有效<br>和具有成本效益的藥物

提供安全、有效
和具有成本效益的藥物

Delivery safe, efficacious
and affordable medicines

AP Biosciences Milestone

2024

Successfully raised 22 million in funding for B round
Series D round of $38 Million was closed

2023

Patient enrollment started for the Phase I trial of AP505/B1962 at Shanghai Pulmonary Hospital

Listed on the Emerging Stock Market Initiation of patient enrollment for Phase III trial of IBI302 for nAMD, originated by AP Bio and licensed to Innovent Patient enrollment started for the Phase I trial of AP505/B1962 which was licensed to Tasly Pharmaceutical Group for China right APBio listed on TPEx Emerging Stock Board (6945.TW) Enrollment of the first patient for Phase I trial of AP203

2022

Successfully secured 25 million in funding for the C round
Series C round of $25 Million was closed

2020

Successfully raised 22 million in funding for B round
Series B round of $22 Million was closed successfully

2019

AP505/B1962 was licensed out to Tasly Biopharmaceutical for development, production, and marketing rights in China, Hong Kong and Macao
AP505/B1962 was licensed out to Tasly Biopharmaceutical for development, production, and marketing rights in China, Hong Kong and Macao

Stock Symbol

6945.TW

stock01.png
Governance
Learn More
stock02.png
Investor Information
Learn More
stock03.png
Financial
Learn More

News

Learn More

11.21 2024

Six bispecific antibody companies you should know about

AP Biosciences has been recognized by the European media Labiotech as one of the world's top six emerging companies in bispecific antibody development, highlighting its advanced antibody engineering capabilities and market influence.

10.21 2024

APBio Partner, Innovent Biologics, Shares Positive Clinical Data for IBI302 at AAO 2024

Innovent Biologics, presented encouraging Phase 2 clinical results for IBI302—a dual-targeted anti-VEGF/complement therapy for nAMD.

09.18 2024

Two targets, one solution: The rise of bispecific antibodies

Bispecific antibodies are currently receiving significant attention in the biopharma industry, and it is expected that more bispecific antibodies will be approved in the future.

09.04 2024

Nikkei News Repost: Taiwan's Growing Bioindustry

AP Biosciences, founded in 2013 in Taiwan, specializes in bispecific antibody drug development. Led by Dr. Jeng Her, who previously co-founded KaloBios Pharmaceuticals in the U.S.. Encouraged by Taiwan's policies, Dr. Her returned to establish AP Biosciences after successfully taking his U.S. company public.

06.01 2024

AP Biosciences Inc completed its Series D financing with 38 million USD raised in June 2024

AP Biosciences Inc completed its Series D financing with 38 million USD raised in June 2024
↑
關閉

建議您使用以下瀏覽器觀看本網站，
以獲得最佳瀏覽效果。

要下載瀏覽器，請直接點擊以下: